A Look At Kymera Therapeutics (KYMR) Valuation After Positive KT-621 Atopic Dermatitis Data
Kymera Therapeutics (KYMR) has garnered attention due to positive Phase 1b data for its KT-621 drug in atopic dermatitis, leading to significant share price growth. Despite a current trading price of $85.40, analysts project a fair value of $119.14, suggesting the stock is undervalued by 28.3%. However, investors should consider the company's high P/B ratio compared to the industry and the inherent clinical and funding risks associated with its R&D heavy strategy.
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares
Kymera Therapeutics Director Elena Ridloff recently sold a total of 12,000 shares across two transactions, totaling approximately $1.025 million. These sales occurred on April 1st and March 31st at average prices of $85.42 and $85.37, respectively. The company also reported missing Q4 earnings estimates, but analysts maintain a "Moderate Buy" rating with a target price of $118.90.
Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Jeremy Chadwick, COO of Kymera Therapeutics, sold 7,600 shares of KYMR stock for $648,888 on March 31st, reducing his stake by 11.05%. This transaction comes as Kymera Therapeutics missed its quarterly earnings and revenue expectations, reporting an EPS of ($0.97) against a consensus of ($0.77) and revenue of $2.87 million against an expected $14.8 million. Despite the recent financial misses, analyst sentiment for Kymera Therapeutics remains mixed but leans toward a "Moderate Buy" with an average target price of $118.90.
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick sold 14,640 shares of the company's stock for over $1.25 million, reducing his stake by 19.3%. This sale aligns with the company's recent weak financial performance, including an EPS miss and a significant revenue decline. Despite these results, analysts maintain a "Moderate Buy" rating with an average price target of $118.90.
Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock
Kymera Therapeutics director Elena Ridloff sold a total of 12,000 shares of KYMR stock on March 31 and April 1, totaling approximately $1.02 million. This included a $631,738 sale of 7,400 shares at $85.37 on March 31. The company recently missed quarterly earnings and revenue estimates, though it holds a "Moderate Buy" consensus rating from analysts with an average target price of $118.90.
Kymera Therapeutics COO sells $1.9 million in shares By Investing.com
Kymera Therapeutics COO Jeremy G. Chadwick sold 22,240 shares of common stock for approximately $1.9 million on March 31 and April 1, 2026. This sale, executed under a Rule 10b5-1 trading plan, followed a 237% stock rally and occurred while the stock was deemed overvalued by InvestingPro. Chadwick also exercised options for the same number of shares, increasing his direct ownership to 61,202 shares after these transactions.
Ridloff Elena, director at Kymera, sells $1m+ in KYMR stock
Kymera Therapeutics director, Elena Ridloff, sold 12,000 shares of KYMR common stock for over $1 million on March 31 and April 1, 2026, while also exercising options to acquire an equivalent number of shares. This transaction occurred amidst other company news, including the presentation of KT-621 clinical trial data for atopic dermatitis and updated price targets from several analyst firms.
Kymera Therapeutics (NASDAQ: KYMR) director sells 12,000 shares under 10b5-1 plan
Kymera Therapeutics director Elena Ridloff exercised stock options for 12,000 shares at $14.18 per share and subsequently sold all 12,000 shares in open-market transactions at average prices between $85 and $86. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan, with the director reporting no directly held common shares after the sales. The filing highlights an exercise-and-sell pattern, contributing to a net-sell direction for these specific grants.
Kymera (KYMR) COO sells 22,240 shares after exercising options
Kymera Therapeutics, Inc.'s Chief Operating Officer, Jeremy G. Chadwick, exercised stock options for 22,240 shares at an exercise price of $29.64 and subsequently sold all 22,240 shares in open-market transactions. These sales, conducted on March 31 and April 1, 2026, were made at weighted average prices between $85.02 and $85.97 per share, pursuant to a pre-established Rule 10b5-1 trading plan. Following these transactions, Chadwick directly owns 61,202 shares of Kymera common stock.
Form 144 and 10b5-1 sales reported for KYMR (NASDAQ: KYMR)
A Form 144 was filed for Kymera Therapeutics, Inc. (KYMR), reporting a proposed sale of 14,640 common shares resulting from an exercise of stock options on April 1, 2026. The filing also detailed multiple prior 10b5-1 sales by Jeremy Chadwick in March 2026, including significant transactions on March 23, 2026, and March 25, 2026, with associated proceeds. This document provides transparency regarding insider stock transactions and their potential market impact.
Kymera's eczema drug gets fast track designation in the United States
Kymera Therapeutics announced that its eczema drug, KT-621, has received Fast Track designation from the U.S. Food and Drug Administration (FDA). This designation is expected to accelerate the development and review process for the drug, which is being investigated for the treatment of moderate-to-severe atopic dermatitis. The move highlights the potential and urgent need for new therapies in this area.
[144] Kymera Therapeutics, Inc. SEC Filing
This article details a Form 144 SEC filing by Kymera Therapeutics, Inc. (KYMR) on March 31, 2026, indicating a proposed sale of 7,400 common shares with an aggregate market value of $588,152. The shares were acquired through the exercise of stock options on the same date. The filing notes that the transaction was made through Morgan Stanley Smith Barney LLC Executive Financial Services.
[144] Kymera Therapeutics, Inc. SEC Filing
A Kymera Therapeutics affiliate reported multiple sales of Common Stock under a Rule 10b5-1 plan and an exercise-based sale in March 2026. The SEC Form 144 filing details these planned dispositions, including dates, share counts, and gross proceeds. It also notes an exercise of stock options for 7,600 shares with cash consideration.
Behavioral Patterns of KYMR and Institutional Flows
This article analyzes Kymera Therapeutics Inc. (NASDAQ: KYMR) using AI models, identifying a mid-channel oscillation pattern and a favorable 45.4:1 risk-reward setup targeting a 13.1% gain. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, showing strong near-term and long-term signals for KYMR.
How Investors Are Reacting To Kymera Therapeutics (KYMR) Oral STAT6 Degrader’s Positive Phase 1b Atopic Dermatitis Data
Kymera Therapeutics (KYMR) recently released positive Phase 1b data for KT-621, its oral STAT6 degrader for moderate-to-severe atopic dermatitis, showing significant biomarker effects and clinical improvements. This data could strengthen the investment case for Kymera's protein degradation platform in Type 2 disease treatments, potentially increasing focus on future Phase 2b readouts. Despite encouraging early results, investors are advised to consider the company's high R&D spend and the risk of unprofitability if later trials do not confirm these findings.
JPMorgan Chase & Co. Lowers Stock Position in Kymera Therapeutics, Inc. $KYMR
JPMorgan Chase & Co. decreased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 7.2% in the third quarter of 2025, selling 15,023 shares. This reduction brings their total holding to 192,699 shares, valued at approximately $10.9 million. The article also highlights significant insider selling and Kymera Therapeutics missing earnings and revenue estimates, though analysts still maintain a "Moderate Buy" consensus rating with an average projected price of $118.90.
Kymera Therapeutics Presents BroADen Study Data on KT-621 at AAD Annual Meeting
Kymera Therapeutics presented data from its BroADen study on KT-621 at the American Academy of Dermatology (AAD) Annual Meeting. The presentation detailed the efficacy and safety profile of KT-621 as a potential treatment for dermatological conditions, showing positive patient outcomes and tolerability. These findings are significant for advancing therapeutic options for various skin-related disorders.
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology Annual Meeting
Kymera Therapeutics announced positive results from its BroADen Phase 1b atopic dermatitis trial for KT-621, an oral STAT6 degrader. The data, presented at the American Academy of Dermatology Annual Meeting, showed significant reductions in STAT6 and inflammatory biomarkers, leading to encouraging clinical improvements in patients. Parallel Phase 2b trials for KT-621 in atopic dermatitis and asthma are ongoing, with results expected by mid to late-2027.
Once-daily KT-621 cut dermatitis severity 63% in early trial
Kymera Therapeutics presented positive Phase 1b results for its oral STAT6 degrader KT-621 in moderate-to-severe atopic dermatitis patients. The trial showed a median STAT6 degradation of up to 98% in blood and a 63% mean reduction in EASI scores after 28 days of once-daily dosing. With favorable safety, parallel Phase 2b trials for atopic dermatitis and asthma are ongoing, with data expected by mid and late-2027, respectively.
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
Kymera Therapeutics has updated its bylaws, designating U.S. federal district courts as the exclusive forum for federal securities litigation. This move aims to centralize legal proceedings and reduce uncertainty following recent changes in Delaware corporate law. The company's stock, KYMR, currently holds a "Neutral" rating from TipRanks' AI Analyst, citing strong pipeline momentum but weak financial performance.
Kymera Therapeutics (KYMR) sets federal courts as exclusive forum for securities claims
Kymera Therapeutics, Inc. (KYMR) has amended its bylaws to designate federal district courts as the exclusive forum for litigation arising under the Securities Act of 1933 or the Securities Exchange Act of 1934. This change, approved by the Board of Directors on March 25, 2026, aligns the company's governance with recent updates to Delaware General Corporation Law concerning forum selection provisions. The amendment is effective immediately, with the full text available in an 8-K filing.
Vanguard Group (NYSE: V) reports 0 KYMR shares after realignment
Vanguard Group (NYSE: V) filed an amended Schedule 13G/A, reporting 0 shares of Kymera Therapeutics Inc. (KYMR) common stock and 0% ownership. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. The filing states that The Vanguard Group, Inc. no longer beneficially owns the securities held by these subsidiaries.
Hedge Fund and Insider Trading News: Catherine Wood, Ray Dalio, Bill Ackman, Warren Buffett, Two Sigma Advisors, MGM Resorts International (MGM), Kymera Therapeutics Inc (KYMR), and More
This article provides a roundup of recent hedge fund activities and insider trading news involving prominent figures like Catherine Wood, Ray Dalio, Bill Ackman, and Warren Buffett. It highlights significant stock moves, such as Ark's sale of Meta stock and acquisition of an AI stock, Bill Ackman's shift to AI giants, and insider purchases and sales in companies like MGM Resorts International and Kymera Therapeutics Inc. The report also suggests a promising AI stock that is trading at less than five times its earnings and has generated positive returns in 2025.
Kymera Therapeutics (KYMR) COO sells 115,977 shares after option exercise
Kymera Therapeutics COO Jeremy G. Chadwick exercised stock options to acquire 109,127 shares at $29.64 and subsequently sold 115,977 shares in the open market. The sales occurred across multiple transactions at weighted average prices ranging from the mid-$70s to around $80 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025, leaving him with 61,202 shares directly held.
Kymera Therapeutics (NASDAQ:KYMR) COO Sells $7,063,662.50 in Stock
Kymera Therapeutics' COO, Jeremy Chadwick, sold 91,250 shares of the company's stock for over $7 million, reducing his direct ownership by nearly 60%. This sale occurred after Kymera missed its quarterly earnings and revenue estimates. Despite the insider selling and financial misses, analysts largely maintain a bullish stance on KYMR, with a "Moderate Buy" consensus and an average price target of $118.90.
Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Jeremy Chadwick, COO of Kymera Therapeutics (NASDAQ:KYMR), sold 24,727 shares of the company's stock on March 25th for approximately $1.98 million, reducing his direct stake by 28.78%. Despite Kymera missing its quarterly earnings and revenue expectations, institutional investors have been increasing their holdings, and analysts maintain a "Moderate Buy" rating with a consensus target price of $118.90. The stock traded up 6.1% to $78.93 on the day of the sale.
Kymera Therapeutics COO sells $9m in shares
Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, sold over $9 million in company stock through a pre-arranged trading plan. Concurrently, he exercised options to acquire additional shares. This comes as the stock shows significant annual growth but is down from its 52-week high, with InvestingPro indicating it may be overvalued.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Analysts
Kymera Therapeutics (NASDAQ:KYMR) has received a "Moderate Buy" consensus rating from twenty-two analysts, with an average 12-month price target of $118.90, despite reporting poor quarterly results that missed revenue and EPS expectations. Additionally, the article highlights significant insider selling, with 196,561 shares worth approximately $17.1 million sold in the last 90 days. Despite these challenges, major financial firms have recently raised their price targets for the stock.
A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection
Kymera Therapeutics (KYMR) is gaining attention after announcing that data for its oral STAT6 degrader KT-621 will be presented at the 2026 American Academy of Dermatology meeting. Despite a market capitalization of US$6.36 billion and strong multi-year returns, the article questions whether the market has already factored in future growth from KT-621. The prevailing narrative suggests Kymera is 34.9% undervalued with a fair value estimate of $119.71, based on its pipeline and significant cash runway.
Kymera’s KT-621 Faces "Sell the News" Risk as AAD Data and Dilution Collide
Kymera Therapeutics (KYMR) stock has seen a significant rise, but its upcoming AAD data presentation for KT-621 carries "sell the news" risk, especially due to a recent $500 million equity offering. The market has already priced in high expectations, meaning the data needs to be exceptional to drive further gains and overcome the dilution. Investors are watching for strong efficacy and safety, particularly against Dupixent, with further clinical trials expected by mid to late 2027 to validate the drug's long-term commercial potential.
A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection
Kymera Therapeutics (KYMR) is gaining attention as its Phase 1b data for oral STAT6 degrader KT-621 will be presented at the 2026 American Academy of Dermatology meeting. Despite a recent share price decline, Kymera has shown strong multi-year returns, with its stock currently trading at US$77.91 against a fair value estimate of US$119.71, suggesting it is undervalued. The company's significant cash runway provides support for its R&D activities and potential long-term growth.
KYMR (KYMR) Form 144 shows option exercise and 10b5-1 sales by insider
Kymera Therapeutics, Inc. (KYMR) has filed a Form 144 disclosing an insider's option exercise and 10b5-1 sales. The filing indicates an exercise of 2,500 stock options for cash on March 20, 2026, and previous 10b5-1 sales by Pamela Esposito of 2,500 shares on February 20, 2026, and 5,500 shares on January 20, 2026, with associated proceeds for each transaction. This report provides details on the securities involved, the acquisition nature, and prior sales activity.
Kymera Therapeutics (KYMR) director exercises options, sells 2,500 shares under 10b5-1 plan
Kymera Therapeutics director Pamela Esposito exercised options for 2,500 shares and immediately sold them under a pre-arranged Rule 10b5-1 trading plan. The shares were sold in three open-market transactions at weighted average prices between $77.71 and $79.94, after being exercised at $49.10 per share. This transaction was disclosed via an SEC Form 4 filing.
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026
Kymera Therapeutics (KYMR) is scheduled to present Phase 1b BroADen trial data for its investigational drug, KT-621, at the American Academy of Dermatology (AAD) conference in 2026. This presentation will share key clinical trial results for KT-621.
Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026
Kymera Therapeutics (KYMR) announced it will present Phase 1b clinical trial data for its investigational drug, KT-621, at the American Academy of Dermatology 2026 Annual Meeting. The BroADen trial evaluated KT-621's effectiveness and safety in patients with moderate-to-severe atopic dermatitis. KT-621 is a first-in-class oral medication designed to degrade STAT6, a key driver of Type 2 inflammation, and is also being evaluated in parallel Phase 2b trials for atopic dermatitis and asthma.
Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026
Kymera Therapeutics (KYMR) will present Phase 1b clinical trial data for its investigational drug, KT-621, at the American Academy of Dermatology 2026 Annual Meeting on March 28. The BroADen trial evaluated the drug's safety and effectiveness in patients with moderate-to-severe atopic dermatitis. KT-621 is a first-in-class oral medicine designed to degrade STAT6, a protein key to Type 2 inflammation, and is currently also being evaluated in Phase 2b trials for atopic dermatitis and asthma.
Nextech Cuts Kymera After Its Latest Peak — pause and reflect before making any decisions.
Nextech Invest, Ltd. reduced its holdings in Kymera Therapeutics (NASDAQ:KYMR) by selling 62,013 shares, valued at approximately $4.19 million. Despite the sale, Kymera remains a part of Nextech's portfolio, with the remaining stake valued at $21.70 million. The article notes that this sale is a typical risk management move, especially as Kymera's stock has performed well, and advises investors to consider Kymera's clinical pipeline developments.
(KYMR) Movement Within Algorithmic Entry Frameworks
The article analyzes Kymera Therapeutics Inc. (NASDAQ: KYMR), identifying a mid-channel oscillation pattern and divergent sentiment across various time horizons. It highlights an exceptional 44.7:1 risk-reward setup targeting a 13.1% gain versus 0.3% risk. The analysis provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Nextech Invest Sells $4.19M in Kymera Shares, Stake Value Rises to $21.7M - News and Statistics
Nextech Invest, Ltd. reduced its holdings in Kymera Therapeutics during Q4 2025 by selling 62,013 shares, valued at $4.19 million. Despite this sale, the total value of its remaining stake in Kymera increased to $21.70 million due to stock price movements, now representing 2.1% of the firm's reportable assets. Kymera Therapeutics is a biopharmaceutical company focused on developing therapies for immunological and oncological conditions.
HighVista Strategies LLC Makes New $890,000 Investment in Kymera Therapeutics, Inc. $KYMR
HighVista Strategies LLC has made a new investment of $890,000 in Kymera Therapeutics, Inc., acquiring 15,728 shares. This comes as several institutional investors have adjusted their positions in KYMR, and the company recently reported quarterly earnings that missed analyst estimates. Despite missing earnings forecasts, Kymera Therapeutics has a "Moderate Buy" consensus rating from analysts with an average price target of $118.90.
Holocene Advisors LP Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR
Holocene Advisors LP has acquired a new stake of 840,333 shares in Kymera Therapeutics, Inc. ($KYMR) during Q3, valued at approximately $47.56 million. Despite recent missed quarterly earnings expectations and insider selling, analysts maintain a "Moderate Buy" consensus rating with a target price of $118.90, influenced by multiple price target increases from sell-side firms.
Braidwell LP Takes $15.66 Million Position in Kymera Therapeutics, Inc. $KYMR
Braidwell LP recently acquired a new position of 276,692 shares, valued at $15.66 million, in Kymera Therapeutics, alongside other institutional investors like Federated Hermes and Frontier Capital materially increasing their stakes. Despite this significant institutional interest and several analyst upgrades leading to a "Moderate Buy" consensus and an average price target of $119.50, Kymera reported a weak quarter with missed EPS and revenue estimates, and insiders have been actively selling shares. The company, focused on targeted protein degradation for small-molecule therapies, has a negative net margin and return on equity, and analysts expect a negative EPS for the current year.
Boxer Capital Management LLC Lowers Holdings in Kymera Therapeutics, Inc. $KYMR
Boxer Capital Management LLC significantly reduced its stake in Kymera Therapeutics (NASDAQ:KYMR) by 26.1% in Q3 2025, now holding 319,100 shares valued at $18.06 million. This reduction comes amid recent insider selling by the company's CFO and a director, totaling over $17 million in the past 90 days, despite insiders still owning 16.01% of the company. Kymera Therapeutics also missed its Q3 earnings and revenue estimates, yet analysts maintain a "Moderate Buy" consensus rating with a target price around $119.50.
Kymera Therapeutics, Inc. $KYMR Shares Sold by Checkpoint Capital L.P.
Checkpoint Capital L.P. significantly decreased its stake in Kymera Therapeutics Inc. by 42.3% in Q3, selling 45,241 shares. This comes amidst considerable insider selling totaling $17.1 million over 90 days, even as analysts largely maintain a "Moderate Buy" rating with an average price target of $119.50 despite the company missing Q3 earnings and revenue expectations.
Kymera Therapeutics, Inc. $KYMR Stock Position Lessened by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC reduced its stake in Kymera Therapeutics (NASDAQ:KYMR) by 3.1% in the third quarter, now holding 6.35 million shares valued at $359.4 million. This reduction comes as Kymera missed quarterly earnings and revenue estimates, alongside significant insider selling totaling over $17 million in the last 90 days. Despite this, several other hedge funds increased their positions, and analysts generally maintain a favorable "Moderate Buy" rating with a consensus target price of $119.50.
Can Kymera Therapeutics’ (KYMR) Oral Degraders Redefine Its Long-Term Edge Over Biologic Rivals?
Kymera Therapeutics is making progress with its oral protein degraders, KT-579 and KT-621, which aim to offer high efficacy with the convenience of small molecules. While these advancements boost the scientific potential, the company faces financial challenges, including rising losses and a high burn rate, requiring careful management to fund late-stage data without significant dilution. The article suggests investors evaluate Kymera's long-term potential against its current financial outlook and the need for clinical success.
Kymera Therapeutics CFO presents new immunology strategy at Barclays Healthcare Conference
Kymera Therapeutics announced that its CFO will present recent company progress and new strategic initiatives at the Barclays Global Healthcare Conference. The presentation will focus on redefining immunology treatment paradigms, offering a detailed update via live webcast. This move emphasizes Kymera's commitment to innovation and leadership in developing novel therapies within the immunology sector.
Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC
Atika Capital Management LLC significantly reduced its stake in Kymera Therapeutics (NASDAQ:KYMR) by 44.5% in the third quarter. Despite this reduction and recent insider selling by the CEO and CFO, analysts maintain a "Moderate Buy" rating with an average target price of $119.50, following recent price target increases from several firms. The company recently missed EPS estimates and experienced a substantial year-over-year revenue decline.
Kymera (NASDAQ: KYMR) COO exercises 20,000 options and sells 25,758 shares
Kymera Therapeutics, Inc.'s Chief Operating Officer, Jeremy G. Chadwick, exercised 20,000 stock options at $43.50 per share and subsequently sold 25,758 shares of common stock in open-market transactions. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted average prices between $82.1275 and $83.7195 per share. Following these transactions, Chadwick directly holds 68,052 shares of Kymera Therapeutics common stock.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 earnings call transcript
This is the Q4 2025 earnings call transcript for Kymera Therapeutics, Inc. (NASDAQ:KYMR). The company discussed its financial results and provided updates on its business operations for the fourth quarter of 2025.
